← All trials
NCT05586230
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 28, 2023
- Primary completion
- Jun 30, 2025
- Completion date
- Jun 30, 2025
- First posted
- Oct 19, 2022
- Last posted
- Oct 19, 2022
- Enrollment
- 72
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)Lead sponsor
- Global Alliance for TB Drug DevelopmentCollaborator
- National Institutes of Health (NIH)Collaborator
- National Institute of Mental Health (NIMH)Collaborator
- Johns Hopkins UniversityStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.